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I. INTRODUCTION
Since 1984, the Food and Drug Administration (“FDA”) has
approved over 8,000 generic drugs, which comprise approximately
seventy-eight percent of currently filled prescriptions.1 The Drug
Price Competition and Patent Term Restoration Act of 1984 (also
known as the “Hatch-Waxman Act”) governs the approval of generic
drugs.2 The Act provides an expedited approval process for generic
drugs that have an identical Reference Listed Drug (“RLD”).
Provided a generic drug is the “same” as its listed drug counterpart,
its manufacturer is permitted to forgo clinical testing, on the
condition that the drug maintains the same label as the listed drug.3
“Sameness” requires the generic drug be the same as the brandname drug in “dosage form, safety, strength, route of
administration, quality, performance characteristics and intended
use.”4 Generic drug manufacturers have no authority to modify or
update their own safety labels if they want to maintain their generic
approval.5 The inability to independently update labels has led to
issues concerning generic drug manufacturers’ liability for failure to
warn of safety concerns, which have recently been addressed by the
U.S. Supreme Court.6
Congress began to combat these concerns with the enactment
of the Generic Drug User Fee Amendments of 2012 (“GDUFA”).7
The GDUFA recognizes the growth of the generic drug industry by
expediting the approval process for generics, saving time and money
1
Fact Sheet: New User Fees for Generic Drugs Will Enhance American’s Access to
Less Expensive Drugs and Generate Major Cost Savings, U.S. FOOD AND DRUG
ADMINISTRATION, http://www.fda.gov/RegulatoryInformation/Legislation/
SignificantAmendmentstotheFDCAct/FDASIA/ucm310992.htm (last visited Mar. 24,
2016).
2
See 21 U.S.C. 355(j) (1)-(2); see also, Drug Price Competition and Patent Term
Restoration Act of 1984 (Hatch-Waxman Amendments) Before the S. Comm. on the
Judiciary, (2003) (statement of Daniel E. Troy, Chief Counsel, U.S. Food and Drug
Administration) available at http://www.fda.gov/newsevents/testimony/
ucm115033.htm.
3
Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Leveling
Before the Energy and Commerce Subcomm. On Health, U.S. H.R., (2014) (statement of
Ralph. G. Neas, President and CEO, The Generic Pharmaceutical Association).
4
Id.
5
Id.
6
Jennifer M. Thomas, FDA Proposes a Rule that Would Undercut Generic Drug
Preemption,
FDA
L.
BLOG
(November
12,
2013,
6:58PM),
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2013/11/fda-proposes-arule-that-would-undercut-generic-preemption.html.
7
Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144,
§908, 126 Stat. 993 (2012).
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for the industry, and ensuring Americans have access to low cost,
quality medicine.8 In exchange for faster approval times, the generic
industry must pay user fees, as branded pharmaceutical drugs are
required to do.9 The GDUFA may be considered the beginning of
major reform for the generic drug industry, placing some of the
same obligations and benefits on the generic industry that the
brand-name manufacturers have dealt with for years.
The growth of the generic industry and the issues presented in
recent Supreme Court cases have prompted the FDA to reconsider
the current federal mandate and to suggest that generic drug
manufacturers be permitted to update safety labels in response to
safety issues that have been discovered.10 The proposed regulation
would require generic drug makers to update their labels in light of
newly acquired safety information to avoid injury to consumers,
which could result in legal liability.11 This Note argues that allowing
generic drug makers to update safety labels as soon as new
information is received will increase patient safety and prevent
injuries by providing timely updates to safety information.12 This
would also allow generic drugs that no longer have a brand-name
counterpart to update their labels.13
These changes may also have an impact on manufacturer’s
exposure to failure-to-warn liability. Under the Supreme Court’s
2011 ruling in PLIVA v. Mensing, generic drug makers are unable to
add new side effect and safety information to product labeling and
therefore should not be held accountable for any failure-to-warn
claims.14 Currently, access to the courts depends on whether an
individual has been prescribed a brand-name or generic drug.15 Dr.
8

Fact Sheet, supra note 1.
Fact Sheet, supra note 1
10
Joe Carlson, FDA’s Generic-Drug Label Rule Draws Controversy, MODERN
HEALTHCARE (June 28, 2014), http://www.modernhealthcare.com/article/20140628/
MAGAZINE/306289979.
11
Id.
12
Id.
13
Id.
14
PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011); Ed Silverman, How Fast Should a
Generic Drug Maker Update Labeling with New Safety Info? THE W.S.J. PHARMALOT, (Sept.
3, 2014, 8:59AM), http://blogs.wsj.com/pharmalot/2014/09/03/how-fast-should-ageneric-drug-maker-update-labeling-with-new-safety-info/; see also Mutual Pharm. Co.
v. Bartlett, 133 S. Ct. 2466 (2013).
15
Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling
Before S. Comm. On Health, Comm. On Energy and Commerce, U.S. H.R., (2014)
(statement of Janet Woodcock, Director, Center for Drug Evaluation and Research,
Food and Drug Administration, Department of Health and Human Service) available
at http://www.fda.gov/NewsEvents/Testimony/ucm389606.htm.
9
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Janet Woodcock, Director of the Center for Drug Evaluation and
Research at the Food and Drug Administration stated that if the
proposed regulatory change is approved, it would allow consumers
to file failure-to-warn claims against generic drug manufacturers.16
Once generic drug makers have the right to change their label, they
would be responsible for knowing the full effects of the drugs they
produce, and may be sued for failing to update their labels in a
timely fashion.17
The FDA notice of the proposed rule
acknowledges that the proposed regulation may also change generic
drug manufacturer’s liability.18 Although the proposed regulations
may have a significant impact on generic drug makers’ liability, such
discussion is beyond the scope of this Note.
Part II of this Note will introduce background legislation and
regulations concerning the labeling of brand-name and generic
drugs. It will describe the subsequent amendments to food and
drug legislation in response to the growth of generic drugs over the
past few decades. Part II will also introduce the 2013 proposed
regulatory amendments, which would provide generic
manufacturers the ability to independently update safety labels.
Part III of this Note will discuss the benefits of independent label
changes to public policy and patient safety while keeping costs
significantly lower than brand-name counterparts.
II. BACKGROUND/OVERVIEW
A. Statutory Background
The Federal Food, Drug, and Cosmetic Act (“FDCA”) and the
Public Health Service Act (“PHSA”), “[p]rovide [the] FDA with
authority over the labeling for drugs and biological products.”19 The
Acts also authorize the FDA to “enact regulations to facilitate the
review and approval of applications regarding the labeling for those
products.”20 Section 502(f) of the FDCA states that “a product is
misbranded unless its labeling bears adequate directions for use,
including adequate warnings against, among other things, unsafe
dosage, methods, duration of administration, or application.”21
16

Id.
Carlson, supra note 10.
18
Ezra Friedman & Abraham L. Wickelgren, Who (if Anyone) Should be Liable for
Injuries from Generic Drugs? NORTHWESTERN LAW & ECON RESEARCH PAPER NO. 14-19 (Oct.
13, 2014) (citing 67986 Federal Register, Vol 78, No. 219, November 13, 2013).
19
See 21 U.S.C. § 301 (2016); see also 42 U.S.C. § 201 (2016).
20
Woodcock, supra note 15.
21
Woodcock, supra note 15.
17
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According to Section 502(j) of the FDCA, “a product is misbranded
if it is dangerous to health when used in the manner prescribed,
recommended, or suggested in its labeling.”22 These statutory
provisions created new standards for drug manufacturer’s products
and facilities.
In 1984, the FDCA was amended to include the Drug
Competition and Patent Term Restoration Act, more commonly
known as The Hatch-Waxman Act.23 The Hatch-Waxman Act
provided a less stringent approval process for generic drug makers.
The generic manufacturer is now required to submit an abbreviated
new drug application, showing the generic drug is the “same” as a
previously approved brand-name drug, and the generic is
“bioequivalent” to the brand-name drug.24 Under the “sameness”
requirement, the generic manufacturer must show that the generic
drug meets the same standards of safety and efficacy, by proving that
the generic drug has the same active ingredient, is identical in
strength, dosage and administration, and has the same safety label.25
The Hatch-Waxman Act exempted generic manufacturers from the
“expensive, time-consuming, and ultimately repetitive clinical
testing and trials that already had been performed on the innovator
drug.”26 In the twenty-two years preceding the Act, only fifteen
generics had been approved by the FDA.27 One year after the Act,
more than 1,000 drugs were submitted for approval to the FDA.28
Hatch-Waxman has resulted in billions of dollars of savings to the
health care industry and consumers.29
Currently, for most substantive changes to drug labeling, a
brand-name manufacturer must submit an approval supplement
and obtain FDA approval of the proposed labeling modification.30
FDA regulations also require manufacturers of pharmaceutical and
biological products to submit reports of adverse drug experiences
22

Woodcock, supra note 15.
Brian Wolfman & Anne King, Mutual Pharmaceutical Co. v. Bartlett and Its
Implications, U.S.L.W. (Sept. 19, 2014), available at http://scholarship.law.georgetown.
edu/facpub/1297.
24
Id.
25
Neas, supra note 3.
26
Neas, supra note 3.
27
Neas, supra note 3.
28
Neas, supra note 3.
29
Neas, supra note 3.
30
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, 78 Fed. Register 67985 (proposed Nov. 13, 2013), available at
https://www.federalregister.gov/articles/2013/11/13/2013-26799/supplementalapplications-proposing-labeling-changes-for-approved-drugs-and-biological-products.
23
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that occur after approval.31 In the interest of public health, the
FDCA permits certain labeling changes based on newly acquired
safety information about the drug when the manufacturer submits
a “changes being effected” (“CBE-0”) supplement describing the
change.32 Newly acquired safety information is defined by the
FDCA as, “. . .information derived from a clinical trial, an adverse
event report, a post approval study . . . peer reviewed biomedical
literature, data derived from the post-market risk identification and
analysis system under section 505(k); or other scientific data
deemed appropriate by [the FDA].”33 When this information is
received, the brand drug must update their warnings labels to reflect
the new information.34
The CBE-0 supplement regulations, “. . .allow application
holders to comply with the requirement to update labeling
promptly to include a warning about a clinically significant hazard
as soon as there is reasonable evidence of a causal association with
a drug . . . .”35 According to the 2008 amended regulations
governing the CBE-0 process, a CBE-0 labeling supplement is only
appropriate to show new information.36 The 2008 amendments
clarified that the supplement may be used to “add or strengthen a
contraindication, warning, precaution, or adverse reaction only if
there is sufficient evidence of a causal association with the approved
product.”37 The FDA reviews all labeling changes proposed in a
CBE-0 supplement and the underlying data and research supporting
the change.38
The FDA then accepts, rejects, or requests
modifications to the proposed changes as deemed appropriate, and
can bring enforcement action if the information makes the
product’s label false or misleading.39 If the newly acquired
information brings to light that the product no longer meets FDA
standards, the agency may choose to rescind the drug’s approval.40
31

Id.
Id.; See also 21 C.F.R. § 314.70(c) (6) (iii); 21 C.F.R. § 601.12(f) (1).
33
See 21 U.S.C. § 505(o)(2)(C).
34
See 21 U.S.C. § 505(o) (2) (C).
35
See 78 Fed. Register 67985; see also 21 C.F.R. § 201.57(c).
36
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, 78 Fed. Register 67985-02 (proposed Nov. 13, 2013) (to be
codified at 21 C.F.R. pt. 314 and 601) available at https://www.federalregister.gov
/articles/2013/11/13/2013-26799/supplemental-applications-proposing-labelingchanges-for-approved-drugs-and-biological-products.
37
Id.
38
Id.
39
See 21 U.S.C. § 352(a).
40
See 21 U.S.C. §§ 355(e), 355-1.
32
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B. The 2012 Enactment of FDASIA/GDUFA: Paving the Way for
Generic Label Updating
In 2010, seventy-eight percent of pharmaceutical prescriptions
were filled with generic brands.41 Today, the top ten drugs filled in
America are all generic brands.42 Over the past decade, generic drugs
have provided a savings of over $824 billion dollars to the nation’s
health care system.43 In response to the rapid growth of generic
drugs over the past decades, Congress, in 2012, enacted the Generic
Drug User Fee Act (“GDUFA”) as a part of the Food and Drugs
Administration Safety and Innovation Act (“FDASIA”).44 GDUFA
allows for more speed in approving generic drugs while ensuring
safety and low costs by requiring generic manufacturers to pay fees
to supplement the costs of reviewing generic drug applications and
inspecting facilities.45 As the FDA has explained, “[r]ecognizing the
critical role generic drugs play in providing more affordable,
therapeutically equivalent medicine, the Generic Drug User Fee
program is designed to keep individual fee amounts as low as
possible to supplement appropriated funding to ensure that
consumers continue to receive the significant benefits offered by
generic drugs. . .”46
The FDASIA gives the FDA the authority to collect user fees
from the pharmaceutical industry to “fund reviews of innovator
drugs, medical devices, generic drugs and biosimiliar biological
products.”47 The FDASIA also encourages innovation by providing
a “breakthrough therapy” designation for certain drugs that may be

41
Gary Gatyas, IMS Institute Reports U.S. Spending on Medicines Grew 2.3 Percent in
2010, to $307.4 Billion, IMS HEALTH (April 19, 2011), http://www.imshealth.com
/en/about-us/news/ims-institute-reports-u.s.-spending-on-medicines-grew-2.3percent-in-2010,-to-$307.4-billion.
42
Karen von Koeckritz, Generic Drug Trends- What’s Next? (April 11, 2012),
http://www.pharmacytimes.com/publications/issue/2012/April2012/Generic-DrugTrends-Whats-Next.
43
Generic Drug User Fee Act Program Performance Goals and Procedures, (Nov. 10,
2014), available at http://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrug
UserFees/UCM282505.pdf.
44
Fact Sheet, supra note 1.
45
Generic Drug User Fee Amendments of 2012, U.S. Food and Drug Administration,
(Nov. 10, 2014), available at http://www.fda.gov/ForIndustry/UserFees/Generic
DrugUserFees/default.htm; See 112 H.R. 3988, 112th Cong. (2012).
46
Generic Drug User Fee Act Program Performance Goals and Procedures, supra note
43.
47
Food and Drug Administration Safety and Innovation Act (FDASIA), U.S. Food and
Drug Administration (Jan. 1, 2015), available at https://www.gpo.gov/fdsys/pkg/PLAW112publ144/pdf/PLAW-112publ144.pdf.
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substantially superior to current drugs on the market.48 This
designation would allow for an expedited review and approval
process through the collection of fees to create additional
resources.49 The FDASIA protects the drug supply chain and ensures
patients have access to drugs they need by extending the FDA’s
detention authority and increasing penalties for adulterated and
counterfeit drugs.50
The purpose of the GDUFA is to increase safety by requiring
that any manufacturer who participates in the U.S. generic drug
industry is inspected biennially.51 It also will “deliver greater
predictability and timeliness to the review of generic drug
applications, slashing review times and saving industry time and
money.”52 The GDUFA also requires that any domestic or
international facility involved in the manufacture of generic drugs
and their ingredients be identified upon their sale in the United
States to increase transparency in the complex, global
pharmaceutical market.53 All facilities and companies selling
generic drugs must register annually with the FDA.54 This includes
manufacturers of active pharmaceutical ingredients whose products
may be used in US products through another manufacturer or
facility that repackages generic drugs.55 The FDA has laid out
guidance on which companies need to self-identify and what
information they are required to provide to the FDA.56 In its
guidance documents, the FDA explained that “[t]he information
provided through self-identification will enable quick, accurate and
reliable surveillance of generic drugs and facilitate inspections and
compliance.”57
The GDUFA also aims to cut down the review time of generic
drug applications from thirty-one months to about ten months.58
48
49
50
51

Id.
Id.
Id.
Generic Drug User Fee Act Program Performance Goals and Procedures, supra note

43.
52

Fact Sheet, supra note 1.
Fact Sheet, supra note 1.
54
H.R. 3988, 112th Cong. (2012); see also Alexander Gaffney, FDA Releases
Guidance on Facility Registrations, Payment Under GDUFA, Regulatory Affairs
Professionals Society (Jan. 21, 2015), http://www.raps.org/regulatoryDetail.aspx?id
=7435.
55
Id.
56
Id.
57
Id.
58
Thomas Sullivan, The Food and Drug Administration Safety and Innovation Act
53
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The funds collected from the user fees, which is stated to be one half
of one percent of generic drug sales, will be used to assess the safety
of generic drugs.59
The user fees result in benefits to the public health by financing
the FDA to carry out functions that it could not do previously.60 By
cutting the review time of a generic drug application, the GDUFA
will increase savings in development time, while decreasing the
costs of bringing a generic drug to the market.61 Therefore, this may
also result in a decline in costs to consumers.62
C. Recent Supreme Court Cases
Recent Supreme Court cases have addressed the issue of
whether generic drug manufacturers should be liable for failing to
provide adequate warnings on drug labels.63 This wave of lawsuits
began with Wyeth v. Levine in 2009.64
In Wyeth, the patient was injured by using a brand-name antinausea drug through an IV-push method.65 The patient claimed the
drug’s label was defective because it failed to instruct clinicians to
use an IV-drip method, rather than the higher-risk push method.66
The patient filed a failure-to-warn suit in state court against the drug
manufacturer, Wyeth, for failing to update the product’s label with
newly acquired safety information, even though the labels
conformed to FDA regulations.67
The Supreme Court determined that federal law does not
preempt a state law failure to warn claim that a brand-name drug’s
(FDASIA): Summary of GDUFA, MDUFA, BsUFA and Pediatrics, Policy and Medicine
(Nov.
10,
2014),
http://www.policymed.com/2012/07/the-food-and-drugadministration-safety-and-innovation-act-fdasia-summary-of-gdufa-mdufabsufa.html.
59
Id.
60
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
61
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
62
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
63
Woodcock, supra note 15.
64
Wyeth v. Levine, 555 U.S. 555 (2009).
65
See Wyeth, 555 U.S. at 559; see also Marie Boyd, Unequal Protection Under the Law:
Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs, 35
CARDOZO L. REV. 1525, 1530 (2014).
66
Id.
67
Jacob Goldstein, Wyeth v. Levine: The Mother of All Preemption Cases, W.S.J. BLOGS
(Sept. 19, 2008, 8:21AM), http://blogs.wsj.com/health/2008/09/19/wyeth-v-levinethe-mother-of-all-preemption-cases.
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label did not contain an adequate warning.68 The Court explained
that “[i]t has remained a central premise of federal drug regulation
that the manufacturer bears responsibility for the contents of its
label at all times.”69 The court held that the manufacturer must
create an adequate safety label and ensure it is up to date as long as
the product is being sold.70 The Court opined “Wyeth failed to
demonstrate that it was impossible for it to comply with both
federal and state requirements . . . the mere fact that the FDA
approved . . . [the] label does not establish that it would have
prohibited such a change.”71 The Court held that Wyeth could have
strengthened the warning labels under the FDA’s CBE-0 regulation
to comply with state law.72 The Court’s holding in Wyeth sent a clear
message to brand-name drug manufacturers that “if they do not
unilaterally strengthen their labels when they know it is necessary,
they will face liability in the state court system.”73
In 2011, the Supreme Court distinguished Wyeth in the
subsequent case PLIVA Inc. v. Mensing.74 In PLIVA, the patients
alleged they developed tardive dyskinesia after using the generic
drug metoclopramide.75 The patients claimed the generic drug label
did not contain adequate warnings of this adverse side effect.76 The
manufacturer of the drug argued that: “(1) FDA regulations require
the warnings on generic pharmaceuticals to be the same as those of
the brand-name product; and (2) they had no ability to unilaterally
add or strengthen warnings without FDA approval.”77 The Court
agreed with the manufacturer and held the claim was preempted
because generic manufacturers cannot add further warnings without
violating FDA regulations under the Hatch-Waxman Act.78

68

Woodcock, supra note 15.
Wyeth, 555 U.S. at 570-71.
70
Id.
71
Wyeth, 555 U.S. at 573.
72
Boyd, supra note 65, at 1530.
73
Sarah S. James, Generic Drug Manufacturer Liability: Achieving a Balance Between
Consumer Affordability and Safety, 38 IOWA J. CORP. L. 177, 182 (2013).
74
PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 at 2581.
75
Id. at 2573.
76
Id. at 2569; Beth S. Rose, Charles J. Falletta & Vincent R. Lodato, Pliva, Inc. v.
Mensing - United States Supreme Court Holds That Failure To Warn Claims Against Generic
Pharmaceutical Manufacturers Are Pre-Empted By Federal Law, NAT’L L. J., Nov. 10, 2014,
http://www.natlawreview.com/article/pliva-inc-v-mensing-united-states-supremecourt-holds-failure-to-warn-claims-against-generic.
77
Rose et al., supra note 76.
78
Rose et al., supra note 76.
69
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The holdings in Wyeth and PLIVA suggest “the Supreme Court
has determined that generic manufacturer’s lack of independence
with respect to drug safety labeling makes it impossible for them to
comply with both Federal drug labeling requirements, and state tort
law (failure-to-warn or design-defect) requirements.”79
The
Supreme Court’s holdings in both cases suggests that access to the
courts depends on whether a consumer purchased a generic or a
brand-name drug.80
In 2013, the Supreme Court decided Mutual Pharmaceutical Co.
v. Bartlett.81 In Bartlett, the plaintiff suffered an adverse effect from
taking the generic medication Sundilac.82 The patient, who took the
prescribed medication to alleviate muscle pain, developed Stevens Johnson syndrome and toxic epidermal necrolysis and became
disfigured as a result.83 This side effect was originally listed as “a
possible adverse reaction” on the safety label and was later moved
to the “warnings” section of the generic label in conformance with
the FDA’s recommendation.84
The Supreme Court held in Bartlett that federal law preempts a
state-law design-defect claim against a generic drug manufacturer
under PLIVA.85 The Court first decided that New Hampshire does
not have a “pure” design-defect cause of action, which would
require a jury to balance the risks and benefits of an FDA approved
drug to determine if it is “unreasonably dangerous.”86 As the FDA
argued in its brief, this would undermine their assurance of
approved drugs on a state-by-state and case-by-case basis, as well as
Congress’ purpose that FDA approvals are made by experts applying
science based judgment.87 The Supreme Court determined that New
Hampshire’s design-defect cause of action includes an evaluation of
the adequacy of the label.88 Through the design-defect analysis, the
Court determined that generic drug manufacturers should not be
held accountable for failure-to-warn or design-defect claims because
generic drug makers are not permitted to independently update
79

Thomas, supra note 6.
Woodcock, supra note 15.
81
See Bartlett, 133 S. Ct. at 2494.
82
Id. at 2472.
83
Id.
84
Wolfman, supra note 23.
85
Bartlett, 133 S. Ct. at 2476; Wolfman, supra note 23.
86
Bartlett, 133 S. Ct. at 2470.
87
Id.; Brief for the United States as Amicus Curiae at 25, Mutual Pharm. Co. v.
Bartlett, 133 S. Ct. 2466 (2013).
88
See Bartlett, 133 S. Ct. at 2470.
80
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safety information on drug labeling.89
Recently, a case has been decided by California’s highest court
that contests the issue of generic drug liability.90 Here, the plaintiff
was injured from her prolonged use of a generic form of Fosamax.91
She claimed that Teva, the generic manufacturer, failed to update
their warnings in compliance with the brand Fosamax’s warnings.92
The defense rebutted that the plaintiff’s claim was preempted by
PLIVA. The trial court held, and the appellate court affirmed, that
since the brand-name drug maker made the safety update, the
generics were at fault for failing to immediately update their labels
to conform to the newly acquired information.93 This case raised
issues about the scope of PLIVA and whether failure-to-update
claims would be preempted by federal law.94 The California
Supreme Court declined to review the decision, therefore the
pharmaceutical company appealed to the United States Supreme
Court.95 The subsequent petition was denied, leaving the decision
about generic drug liability to the FDA.96 The Supreme Court’s
denial of the petition to hear this case may pave the way for similar
failure to warn claims to be brought against generic drug makers in
state court.97
Similarly, the Alabama Supreme Court recently upheld a suit
against brand-name manufacturer for damages caused by the
generic form under the concept of “innovator liability.”98 Here, the
court found brand drugs could be liable because the generic
manufacturers relied on the warnings and labels of the brand drug.99
89
Ed Silverman, Lawmakers Ask White House to Review FDA Rule for Generic Label
Changes, PHARMALOT (Sept. 2, 2014), http://blogs.wsj.com/pharmalot/2014/06/26/
lawmakers-ask-white-house-to-review-fda-rule-for-generic-label-changes/.
90
Teva Pharm. USA, Inc. v. Superior Court, 217 Cal. App. 4th 96 (Cal. App. 4th
Dist. 2013).
91
Id.
92
Id. at 101.
93
Ed Silverman, Supreme Court Declines to Review Case About Generic Labeling,
PHARMALOT (Jan. 21, 2015), http://blogs.wsj.com/pharmalot/2015/01/21/supremecourt-declines-to-review-case-about-generic-labeling/.
94
Id.
95
Id.
96
Id.; see Teva Pharm. USA, Inc. v. Superior Court, 135 S.Ct. 831 (2015).
97
Kang, Y. Peter, High Court Lets Teva Drug Labeling Suit Go Ahead, LAW 360 (Jan.
20,
2015),
http://www.law360.com/articles/612895/high-court-lets-teva-druglabeling-suit-go-ahead.
98
See Weeks v. Wyeth, Inc., No. 1101397, slip op. at 65 (Ala. Aug. 15, 2014).
99
James W. Huston, Erin M. Bosman, and Julie Y. Park. Weeks II: Innovator Liability
Finds a Sweet Home in Alabama, CLIENT ALERT 1 (Aug. 20, 2014),
http://www.mofo.com/~/media/files/clientalert/2014/08/140820weeksIIInnovatorlia
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The court relied on the holding in PLIVA, finding that the federal
regulatory scheme made it foreseeable that the brand-name drug
owed the generic version a duty of care.100 The pharmaceutical
industry fears that this precedent could cause a damaging trend
throughout the U.S. economy.101
D. Proposed FDA Regulation
Under the current federal regulations, a generic drug
manufacturer may only use the CBE-0 supplement process to update
its product labeling to conform to the approved safety label for the
similar brand-name drug.102 A generic drug manufacturer may not
independently file a CBE-0 supplement to the FDA in light of newly
acquired safety information, nor unilaterally change its product’s
label to add information that is different from the brand-name
drug’s label.103
On November 13, 2013, the FDA proposed to add 21 C.F.R.
314.70(c)(8), which amends the current regulations and procedures
that govern the ability to update and change generic drug safety
This proposed rule would allow generic drug
labels.104
manufacturers to independently submit “changes being effected”
(“CBE-0”) supplements to update labels in light of newly acquired
safety information, regardless of whether this information may
differ from the warnings on the brand-name drug.105 The generic
manufacturer would be able to distribute updated safety labels after
submitting a CBE-0 to the FDA, as well as safety information
supporting the change.106 The CBE-0 will also notify the maker of
the listed drug of the newly acquired safety information.107
To make updated safety information readily available to the
public and to avoid confusion, the FDA proposed establishing a
webpage where the FDA will post new safety information acquired
from the CBE-0 supplements.108
bility.pdf.
100
Id.
101
The Threat of ‘Innovator Liability’, WALL ST. J. (March 13, 2013), available at
http://www.wsj.com/articles/SB10001424127887323628804578346231780434760
102
See 21 U.S.C. § 355(j) (1)-(2).
103
Id.
104
21 C.F.R. § 314.70(c)(8); Supplemental Applications Proposing Labeling
Changes for Approved Drugs and Biological Products, supra note 30.
105
21 C.F.R. § 314.70(c)(8).
106
Id.
107
Id.
108
Id.
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This proposed rule would allow a generic drug to display a label
that is temporarily inconsistent with the labels of the listed drug.109
The FDA would then evaluate whether the change is justified and
make a decision on the generic and listed drug change at the same
time, and as a result, both drugs will have the same FDA approved
label.110 After the FDA approves the safety label change, there will
be a thirty day time frame in which all drug manufacturers of the
“same” drug will have to submit a CBE-0 supplement with
conforming label changes.111
The amended regulations would also permit generic drugs
which no longer have a brand-name counterpart to update their
own labels.112 Under current regulations, there is no technique to
accomplish such label change, and therefore, these drugs are being
sold on the market with potentially incorrect or out-of-date safety
information.113 The FDA estimates approximately 420 drugs are
sold only in the generic form, and the listed drug is no longer
manufactured.114 Current FDA regulations also prohibit a generic
drug manufacturer from sending a “Dear Doctor” letter which
would inform physicians of updated and new safety warning
information.115 The FDA views “Dear Doctor” letters as labeling,
therefore a generic is not permitted to send such letter with new
safety information that is different from the brand name label.116
III. REEXAMINING THE CURRENT FDA REGULATIONS TO PERMIT GENERIC
DRUG MANUFACTURERS TO UPDATE SAFETY LABELS
FDA-approved drug labeling provides patients with essential
information needed for the safe and effective use of a drug. Further,
approved labels reflect the FDA’s findings of the safety and
effectiveness under the labeled conditions of use.117 Scholars argue
that “[t]he primary purpose of labeling for prescription drugs is to
109

Id.
Press Release, U.S. Food and Drug Administration, FDA Takes Action To Speed
Safety
Information
Updates
on
Generic
Drugs
(Nov.
8,
2013)
http://fda.gov/newsevents/newsroom/pressannouncements/ucm374171.htm.
111
Woodcock, supra note 15.
112
Carlson, supra note 10.
113
Carlson, supra note 10.
114
Allison Zieve, Guaranteeing Patient Safety, U.S. NEWS,Sept. 22, 2014,
http://www.usnews.com/opinion/articles/2014/03/27/fdas-generic-drug-lableingproposal-guarantees-patient-safety.
115
Boyd, supra note 65 at 1536.
116
Id.
117
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
110
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provide health care practitioners with the essential scientific
information needed to facilitate prescribing decisions, thereby
enhancing the safe and effective use of prescription drug products
and reducing the likelihood of medication errors.”118 This safety
information is used by practitioners and patients to make decisions
about prescription drugs by weighing the stated risks against the
benefits.119
As of 2010, nearly 90% of pharmaceuticals in the United States
are filled with a generic brand despite the availability of a
substitute.120 Despite the changes in the market, and the evolution
of the generic drug industry, the regulations concerning generic
labeling have remained largely unchanged.121
Generic drug makers may not always be able to quickly inform
consumers of updated safety information, because they are not able
to act under the same authority as their brand-name counterparts.122
Generic drugs must maintain an identical label to their brand-name
substitutes, and are only required to update safety labels when the
brand-name has filed a CBE Supplement with the FDA and the
change has been approved.123
A. Public Policy Favors Informing Patients and Physicians of
Changes in Drug Safety Information
The side effects and risks of taking a particular drug may not
come to light until after the drug has been approved by the FDA.124
Therefore, both brand-name and generic makers are required to
have written procedures for the review, surveillance and reporting
of adverse drug information, and any “serious and unexpected” drug
experiences to the FDA.125 Information obtained from any source,
foreign or domestic, or any type of post-marketing study or

118
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
119
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
120
HHS, ASPE Issue Brief: Expanding the Use of Generic Drugs, (Sept. 22, 2014),
available at http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.shtml.
121
Wolfe, Sidney M, Allison M. Zieve & Brian Wolfman. Citizen Petition (Aug. 29,
2011).
122
Silverman, How Fast Should a Generic Drug Maker Update Labeling with New Safety
Info?, supra note 14.
123
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
124
Boyd, supra note 65 at 1535.
125
21 C.F.R. § 312.32(c)(1)(i).
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investigation must be reviewed.126 Both brand-name and generic
manufacturers must comply with postmarking reports by
submitting an annual report to the FDA including a summary of
information that may affect the drug’s safety, effectiveness, or
labeling, as well as a description of the actions taken in response to
the new information and proposed revisions to the safety labels.127
The Supreme Court ruling in PLIVA sparked the concern that
generic labels are not sufficient to warn consumers of the risks
associated with medications.128 Public policy favors informing
health care practitioners and patients of prescription medication
safety information. The public will benefit as a result of
manufacturers updating drug safety labels in response to newly
acquired safety information.129 Allison Zieve, head of the litigation
group at Public Citizen, commented “[n]o drug is safe in all
situations. A drug is safe when used in accordance with labeling that
accurately reflects the known risks. The sooner generic drug
companies are allowed to make safety updates, the better for public
health.”130 The public is harmed when a regulatory delay allows a
safety gap and when relevant information is not readily available to
the affected parties.131 The ability to update safety information will
ensures that patients have the most recent and reliable information
about their medications, and can make an informed choice on
whether to take a prescribed drug.
The proposed amendments to current FDA regulation will
permit generic drug makers to update product labeling to “reflect
data obtained through post-market[ing] surveillance.”132 Although
the proposed amendment does not require generic manufactures to
conduct new clinical tests, it will allow the manufacturers to
inexpensively update labels when adverse information is received
and investigated, while still keeping prices lower than brand-name

126
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
127
Id.
128
Ed Silverman, FDA Delays Final Rule on Allowing Generic Drug Makers to Update
Labels, WSJ PHARMALOT, (Nov. 18, 2014), http://blogs.wsj.com/pharmalot/2014/11/18
/fda-delays-final-rule-on-allowing-generic-drug-makers-to-update-labels/.
129
Woodcock, supra note 15.
130
Silverman, FDA Delays Final Rule on Allowing Generic Drug Makers to Update
Labels, supra note 128.
131
Silverman, FDA Delays Final Rule on Allowing Generic Drug Makers to Update
Labels, supra note 128
132
Woodcock, supra note 15.
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counterparts.133 Some argue prices will increase due to the liability
generic drug makers would face.134 However, proponents believe
generic drug makers will not face an increase in litigation because
lawsuits would be less likely to occur when generic drugs are able to
update safety information, preventing injury from occurring
altogether.135 The FDA states the proposed regulation will “provide
incentive to generic drug companies to actively participate with the
FDA in ensuring the timeliness, accuracy and completeness of drug
safety labeling.”136
Lawmakers believe that”[t]his proposal will help equip health
care providers and consumers who depend on generic drugs with
the best possible information to avoid adverse outcomes.”137 The
public will benefit because both brand-name and generic drug
manufacturers will have the obligation to give doctors and patients
the information necessary to avoid injuries.138 Through this
amendment, the FDA will not only be able to preserve the principal
of “sameness” between brand-name and generic drugs, but will also
allow patients to have better information about a drug’s potential
risks and benefits, regardless of the manufacturer.139
Many opponents of the regulations claim that the time period
where labels may differ will cause confusion and lead to overwarning.140 However, under the current regulations, when a brandname drug has a safety label update, it can take several months
before generic drug manufacturers update their labels with the new
warnings.141 Also, brand-name drugs have possessed the ability to
update their own safety labels for over thirty years, and there has
never been a problem with over-warning of safety information.142
133

See generally note 41.
Toni Clarke, FDA defends generic drug label proposal at U.S. House hearing, REUTERS,
April 1, 2014, http://www.reuters.com/article/2014/04/01/generic
drugs-idUSL1N0MT1IV20140401.
135
Id.
136
Peter C. Neger, FDA Proposes New Change to Generic Labeling Rule,
MARTINDALE.COM (Nov. 13, 2013), http://www.martindale.com/ products-liabilitylaw/article_Bingham-McCutchen-LLP_2028576.htm.
137
Press Release, U.S. Senate Committee on Health, Education, Labor, & Pensions,
Harkin Welcomes FDA’s Release of Proposed Rules to Protect Consumers Using
Generic Drugs (Nov. 8, 2013), available at http://www.help.senate.gov/newsroom
/press/release/?id=fdadb26d-2999-4a09-9766-a2a2f7546701.
138
Id.
139
Id.
140
Zieve, supra note 114.
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Zieve, supra note 114.
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Zieve, supra note 114.
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The confusion concerning the temporary differences in brand
and generic labels will be outweighed by the public health
benefits.143 Dr. Woodcock, opined: “It is expected that a valid safety
concern regarding a generic drug product also would generally
warrant submission of a supplement for change to the labeling by
the application holder for the corresponding brand drug, as well as
other generic drug application holders.”144 Therefore, it can be
assumed when new safety information is acquired, all
manufacturers will apply to change the label, reducing the amount
of differing labels even before the FDA has approved the change.
Further, the FDA will maintain a website tracking CBE-0
supplements, so health care providers and patients will have access
to the newest changes and updates. Once the FDA approves a CBE0 supplement, it will continue to be posted on the site, and a thirtyday timeframe will be established for drug manufacturers to submit
a CBE-0 supplement conforming to the label change.145 This will
cut down the amount of time that differing labels will be available
on the market.146 Under the FDCA, the FDA is authorized to
“require and, if necessary [order] labeling changes if the FDA
becomes aware of new safety information that the FDA believes
should be included in the labeling of the drug.”147 Therefore, the
FDA can implement a rule allowing generic drugs to independently
update warning labels, ensuring the newest warnings are available
to consumers, regardless of whether they take brand-name or
generic medication.
Senator Henry Waxman, co-author of the 1984 Hatch-Waxman
Act, argued that allowing generic drugs to update their labels will
ease customers’ concerns about the danger of taking generic drugs
because they will be aware of the latest risks and safety information.
Waxman further argued that it will aid in preventing consumers
from believing generic drugs are not as safe as brand-name drugs
because generics will have more incentive to warn consumers about
safety issues, and will be able to get the information out to
consumers.148 Generic drug manufacturers have already proven that
143

See Zieve, supra note 114.
Woodcock, supra note 15.
145
Woodcock, supra note 15, at 7.
146
Woodcock, supra note 15, at 7, 9.
147
U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: SAFETY LABELING CHANGESIMPLEMENTATION OF SECTION 505(O)(4) OF THE FD&C ACT, 3 (2013), available at
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/gui
dances/ucm250783.pdf.
148
Tim Devaney, FDA Raises Safety Measure for Generic Drugs. THE HILL, April 1,
144
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generic drugs are equally as safe as the brand-name counterpart and
the FDA has agreed.149 Gary Beuhler, Director of the FDA’s office of
Generic Drugs argued “[m]ost people believe that if something costs
more, it has to be better quality. In the case of generic drugs, this is
not true . . . [t]he standards for quality are the same for brand-name
and generic products.”150
Alison Zieve of Public Citizen has argued, “[a]s generic drugs’
market shares increase, brand-name drugs lose incentive to engage
in safety monitoring.”151 Zieve further argued “[t]he FDA cannot
monitor all post-approval data by itself, drug safety is threatened
when the regulatory and common-law incentives designed to
motivate manufacturer diligence weaken with shifting control of
market share.”152 Because the generic drug has the majority of the
market share, they will probably receive the most reports concerning
risks and adverse experiences using the drug.153
Generic
manufacturers therefore may be in a better position to update
product safety labels because they serve a larger amount of the
population.154 Under the current system, the generic manufacturers
cannot update safety information until the brand-name takes
action.155
Allowing generic drug manufacturers to independently update
product safety labels in light of newly acquired safety information
will be a great benefit to public health by increasing patient safety
and awareness, while keeping costs and confusion at a minimum.
B. Generic Drugs Will Continue to be an Affordable Alternative to
Brand-Name Prescriptions
Generic drugs are more affordable because manufacturers do
2014,
http://thehill.com/regulation/healthcare/202383-fda-raises-safety-measuresfor-generic-drugs.
149
FDA Ensures Equivalence of Generic Drugs, U.S. FOOD & DRUG ADMIN. (Aug.,
2002),
http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparednes
s/ucm134444.htm (quoting Gary Beuhler, Director of FDA’s Office of Generic Drugs).
150
Id.
151
PUBLIC CITIZEN, GENERIC DRUG LABELING, 24 (2013), available at
https://www.citizen.org/documents/2138.pdf.
152
Examining Concerns Regarding FDA’s Proposed Changes to Drug Labeling: Hearing
Before the Comm. on Energy and Commerce, 113th Cong. 7 (2014), (statement of Allison
Zieve, Director, Public Citizen Litigation Group).
153
Id.
154
Id.
155
See Supplemental Applications Proposing Labeling Changes for Approved
Drugs and Biological Products, 78 Fed. Reg. 67985 (proposed Nov. 13, 2013).
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not need to spend money on costly clinical trials. Even if generics
had more responsibility under the proposed regulation, the savings
would still be apparent.156 The proposed rule would assist in
keeping liability costs down by preventing injuries from occurring
in the first place through efficient safety label updates.157 Currently,
generic drugs are shielded from liability because they cannot update
their labels. If a generic drug maker becomes aware of a risk, they
cannot change safety labels, unless the brand-name does so.
Critics of the proposed regulation fear that allowing generic
drug makers to update their product safety labels will open them up
to failure-to-warn lawsuits.158 However, if the injuries had never
occurred, there would be no lawsuit.159 Allison Zieve of Public
Citizen testified in front of the House of Representatives
Subcommittee on Health:
Because immunizing the companies from liability does not make the
injured patients’ costs go away. The medical expenses and lost wages
from lost work time still exist; they are carried by the patients, health
insurers, and taxpayers, through Medicare or Medicaid. Because the
proposed rule will give generic manufacturers the tools and incentive to
update safety labeling, any costs of the rule should be offset by cost
savings—savings in medical care for the patients who will not be injured
because physicians and patients are armed with updated labeling about
safety risks.160

Critics also fear that generic drug manufacturers may over-warn
to avoid liability. However, proponents have noted since the ruling
in Wyeth there has not been a surge in CBE-0 supplements to update
brand-name labels, therefore there should not be a worry for over
warning by generic drug makers.161
According to the FDA, “the main reason generic drug
companies can market their drugs at lower prices is that they don’t
face the same development costs as brand-name companies.”162
Generic drugs are approved through an expedited process, and are
permitted to skip costly clinical trials provided that the drug is the
“same” and the “bioequivalent” of its brand-name counterpart.163
156

Boyd, supra note 65, at 1539.
Zieve, supra note 114.
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Friedman, supra note 18, at 3.
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Friedman, supra note 18, at 10.
160
Examining Concerns Regarding FDA’s Proposed Changes to Drug Labeling: Hearing
Before the Comm. On Energy and Commerce, supra note 152.
161
Boyd, supra note 65 at 1543-44.
162
Michelle Meadows. New FDA Initiatives to Improve Drug Reviews and Reduce Legal
Loopholes, U.S. FOOD & DRUG ADMIN. (Sept./Oct. 2003), http://www.fda.gov/Drugs/
ResourcesForYou/ucm134448.htm.
163
Neas, supra note 3.
157

SEIDEN_FINAL_FORMAT.DOCX (DO NOT DELETE)

2016]

8/23/2016 11:16 PM

INCREASING PATIENT SAFETY

431

The proposed regulation does not place any new requirements for
generic drugs to undergo separate clinical trials and testing,
therefore the costs to consumers should remain low.164 Allison
Zieve stated “[g]eneric competition [also] helps keep the cost of
drugs down . . . it also encourages the research based drug
companies to keep finding new and better medicines that have
patent protection.”165
An estimate published by the consulting firm Matrix Global
Advisors stated the proposed rule would lead to approximately a five
percent annual increase in spending on generic drugs.166 The FDA
has examined the economic impacts of the proposed regulation and
has determined:
the proposed rule would only impose new burdens on small generic drug
manufacturers who submit CBE-0 supplements for safety-related
labeling changes. The FDA believes the impact will not be significant
due to the low cost of submission, and the uncertainty of the amount of
supplements that may be filed.167

C. Allowing Generic Drug Makers to Update Product Safety Labels
will Provide a Means for Generic Drugs which no Longer have
a Brand-name Counterpart to Make Safety Updates
The FDA estimates there is approximately 420 drugs that are
sold only in the generic form.168 The Generic Pharmaceuticals
Association states that number is even larger, estimating that about
45% of generic drugs have no brand-name counterpart.169 There is
a gap in the current regulatory system for generic drugs whose
brand-name drug counterpart is no longer sold on the market. Since
a brand-name drug is only permitted to update safety warnings on
product labels, the generic drugs that no longer have a brand-name
counterpart are left without a means of updating safety label
information.170 Currently, there are no clear and efficient methods
to disseminate information to health care providers, and the public,
about newly discovered safety risks.171

164
165
166
167
168
169
170
171

See generally, Devany, supra note 148.
Devany, supra note 148
Carlson, supra note 10.
Wolfman, supra note 23.
Zieve, supra note 114.
Zieve, supra note 114.
Boyd, supra note 65.
Carlson, supra note 10.
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This is concerning because serious drug risks may not be
identified until after the generic drug enters the market, and several
generic drugs no longer have a corresponding brand-name drug on
the market.172 Without a corresponding brand-name drug, there are
no available resources to conduct ongoing investigations as to the
safety of the drug.173 Therefore, drugs that are only available in
generic form are not continuously monitored or investigated, and
there is no way to update the drug’s label if new safety information
comes to their attention.
IV. CONCLUSION
The FDA has acknowledged the growth of the generic
pharmaceutical industry, and its impact on the United States’ health
industry.
Today, generic drugs fill almost 90% of all
pharmaceuticals in the United States, yet consume only 27% of total
drug spending, resulting in huge savings to American consumers
every year.174
The Hatch-Waxman Act of 1984 allowed generic drugs to be
approved through an abbreviated process, provided the generic drug
was the “same” in ingredients, dosage, and administration, and was
the “bioequivalent” of the brand-name drug.175 The enactment led
to a greater number of generic drug approvals, and millions of
dollars of savings in drug costs to American consumers.176
The FDASIA and GDUFA were enacted in 2012 in response to
the emerging generic drug industry.177 The GDUFA was enacted to
increase safety and accessibility of generic drugs, and provide
transparency by inspecting all generic drug facilities.178 The Act was
designed to expedite the approval process of generic drugs, and as a
result, cut down the backlog of pending approvals.179 As generic
172
173
174
175
176

Carlson, supra note 10.
Carlson, supra note 10.
Neas, supra note 3.
Wolfman, supra note 23.
Generic Drug User Fee Act Program Performance Goals and Procedures, supra note

43.
177
Fact Sheet: New User Fees for Generic Drugs Will Enhance American’s Access to
Less Expensive Drugs and Generate Major Cost Savings, http://www.fda.gov/
RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/uc
m310992.htm (last visited Mar.. 24, 2016).
178
Supplemental Applications Proposing Labeling Changes for Approved Drugs
and Biological Products, supra note 30.
179
Gil Y. Roth, Generic Manufacturing: GDUFA & CMOs, CONTRACT PHARMA, (Nov.
12, 2014), http://www.contractpharma.com/issues/2013-03/view_features/genericmanufacturing-gdufa-cmos/.
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drugs continue to take an increasing amount of market share, the
government has responded by imposing similar burdens and
benefits on generics as brand-name drugs through GDUFA.
Allowing generic drugs to file CBE-0 changes and update labels
would conform to this emerging trend.
The proposed regulation to permit generic drug manufacturers
to update their safety labels without FDA approval, and
independent of the brand-name drug’s label will result in an
increase of safety information that is beneficial to public health.
Patients and physicians will be up to date with the newest safety
information concerning generic drugs, which are used by the
majority of Americans today.
Although this may create temporary differences between
generic and brand-name drug labels, it will increase patient safety
overall. Allowing generic drug manufacturers to independently
update safety labels will also encourage them to monitor and
research the safety of marketed drugs; while also having the
possibility of increasing the quality of the drugs being manufactured
by creating liability for generic products.
Updating the FDA’s current regulations will also create an
opportunity for generic drugs that no longer have a brand-name
counterpart to keep patients up to date on the newest safety
information, and provide a consistent method for updating safety
labels for all drugs and prescriptions in the United States.

